HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cetylpyridinium chloride anti-gingivitis efficacy hinges on re-analysis of Cepacol data.

This article was originally published in The Rose Sheet

Executive Summary

CETYLPYRIDINIUM CHLORIDE EFFICACY VERSUS GINGIVITIS HINGES on a re-analysis of clinical studies using Cepacol mouthrinse that failed to show a significant reduction in gingivitis, panel member Robert Genco, DDS/PhD, suggested at an Aug. 15 meeting of the OTC Plaque Products Subcommittee of FDA's Dental Products Panel. During the meeting, the subcommittee discussed memos prepared by Genco on the safety and efficacy of three anti-plaque/gingivitis ingredients: cetylpyridinium chloride, dicalcium phosphate dihydrate and aloe vera.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS001911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel